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with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and 
NRAS (FOCUS4-D): a phase 2–3 randomised trial
Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk, David Fisher, Richard Kaplan, Phil Quirke, Susan Richman, Leslie Samuel, 
Jenny Seligmann, Matt Seymour, Kai Keen Shiu, Harpreet Wasan, Richard Wilson, Tim Maughan, on behalf of the FOCUS4 Trial Investigators
Summary
Background A substantial change in trial methodology for solid tumours has taken place, in response to increased 
understanding of cancer biology. FOCUS4 is a phase 2–3 trial programme testing targeted agents in patients with 
advanced colorectal cancer in molecularly stratified cohorts. Here, we aimed to test the hypothesis that combined 
inhibition of EGFR, HER2, and HER3 signalling with the tyrosine kinase inhibitor AZD8931 will control growth of all 
wild-type tumours.
Methods In FOCUS4-D, we included patients from 18 hospitals in the UK with newly diagnosed advanced or 
metastatic colorectal cancer whose tumour was wild-type for BRAF, PIK3CA, KRAS, and NRAS. After 16 weeks of 
first-line therapy, patients with stable or responding tumours were randomised to oral AZD8931 (40 mg twice a day) 
or placebo. Randomisation was done by minimisation with a random element of 20%, minimisation by hospital site, 
site of primary tumour, WHO performance status, 16-week CT scan result, number of metastatic sites, and first-line 
chemotherapy regimen. The primary outcome was progression-free-survival. CT scans were assessed by local 
radiologists according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Preplanned interim 
analyses were assessed per protocol and were agreed using multiarm multistage (MAMS) trial design methodology 
triggered by occurrence of progression-free survival events in the placebo group. The final analysis was assessed by 
intention to treat. This trial is registered at controlled-trials.com, ISRCTN 90061546.
Findings Between July 7, 2014, and March 7, 2016, 32 patients were randomised to study treatment, 16 to AZD8931 and 
16 to placebo. At the first preplanned interim analysis (March, 2016), the independent data monitoring committee 
(IDMC) recommended closure of FOCUS4-D because of a lack of activity. At the final analysis (Aug 1, 2016), 31 patients 
had had a progression-free survival event (15 with AZD8931 and 16 with placebo). Median progression-free survival 
was 3·48 months (95% CI 1·51–5·09) in the placebo group and 2·96 months (1·94–5·62) in the AZD8931 group. 
No progression-free survival benefit of AZD8931 compared with placebo was noted (hazard ratio [HR] 1·10, 95% CI 
0·47–3·57; p=0·95). The most common grade 3 adverse event in the AZD8931 group was skin rash (three [20%] of 
15 patients with available data vs none of 16 patients in the placebo group), and in the placebo group it was diarrhoea 
(one [7%] vs one [6%]). No grade 4 adverse events were recorded and no treatment-related deaths were reported.
Interpretation The MAMS trial design for FOCUS4 has shown efficiency and effectiveness in trial outcome delivery, 
informing the decision to proceed or stop clinical evaluation of a targeted treatment within a molecularly defined 
cohort of patients. The overarching FOCUS4 trial is now aiming to open a replacement arm in the cohort with all 
wild-type tumours.
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Introduction 
Signalling through HER receptors—ie, EGFR, HER2, 
HER3, and HER4—and their downstream pathways is a 
key mechanism that promotes proliferation and the 
malignant phenotype in cancer. EGFR has been recognised 
as a key pathogenic surface receptor in colorectal cancer 
for many years. A greater understanding of colorectal 
cancer biology followed by use of EGFR-targeted 
treatments has led to discovery of the importance of BRAF, 
PIK3CA, KRAS, and NRAS mutations in predicting a lack 
of response to EGFR-targeted therapy.1 The monoclonal 
antibodies cetuximab and panitumumab were developed 
to target EGFR on the surface of cancer cells. After 
licensing, cetuximab and panitumumab were reported to 
be ineffective in patients whose cancer expressed a somatic 
mutation in the NRAS or KRAS genes.2 Simple EGFR 
inhibition therefore has limitations, because both de-novo 
and acquired resistance can arise and result in lack of 
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benefit for most of these biomarker-selected patients, thus 
driving interest in novel approaches to inhibit this pathway. 
However, EGFR remains a valid target in colorectal cancer 
within the population of patients wild-type for KRAS, 
NRAS, and BRAF, with proven clinical benefit.
The proteins HER2 and HER3 (also known as ERBB2 
and ERBB3, respectively) heterodimerise with EGFR 
and are mechanisms of resistance to EGFR inhibition. 
HER3 is a membrane-bound receptor protein that has 
extracellular heregulin and neuregulin binding domains 
but does not have an intracellular kinase domain, relying 
on heterodimerisation to other family members for down-
stream effects. HER3 expression is associated with poor 
prognosis in colorectal cancer.3 The protein has a central 
role in driving oncogenic signals in tumours,4 and 
preclinical and clinical data have led to the hypothesis that 
HER3 is an escape pathway to EGFR blockade through a 
compensatory shift to HER3 signalling, predominantly 
through the PI3K/AKT pathway.5–7 Moreover, clinical data 
indicate that HER3 overexpression predicts the lack of 
efficacy of pani tumumab.8 HER2 is another member of 
the EGFR family of membrane-bound receptors. It is an 
orphan receptor, having no known associated ligands, but 
is activated through homodimerism and heterodimeri-
sation with other EGFR family members, resulting in 
intracellular phosphorylation and cascaded downstream 
signalling. Growing in-vitro and in-vivo evidence suggests 
that HER2 might be overexpressed more frequently in 
patients with EGFR-dependent (all wild-type) tumours.9 
Furthermore, this protein might be upregulated in 
acquired EGFR inhibitor resistance, and concomitant 
blockade of HER2 could increase efficacy and prolong 
activity in a synergistic fashion. Bertotti and colleagues10 
developed a range of colorectal cancer xenograft models 
from genetically well-characterised, metastatic colorectal 
cancer samples. A cohort of these so-called xenopatients 
showed amplifi cation of HER2, particularly in RAS 
wild-type tumours, suggesting enrichment in this 
cohort, which showed high and sustained sensitivity to 
combination EGFR and HER2 inhibition. Inhibition of 
EGFR, HER2, and HER3 signal ling is postulated to reduce 
de-novo resistance, thereby increasing the proportion of 
patients showing benefit when compared with inhibition 
of EGFR only. Further more, this inhibition might slow the 
development of acquired resistance in patients with 
initially EGFR-dependent tumours, therefore providing 
greater clinical benefit than EGFR inhibition alone.
The convergence of the molecular understanding of 
colorectal cancer and clinical development of a wide 
range of targeted treatments demands evaluation of new 
agents within biologically defined subsets of patients 
whose tumours are most likely to benefit. Moreover, after 
the failure of many trials to show benefit for a new 
treatment in colorectal cancer, we clearly need a new 
paradigm to attempt to make progress. The idea of one 
research question for all patients is outdated in colorectal 
cancer, as it is with breast cancer, and is increasingly the 
case across all oncology.
We have developed a new approach to trial design that 
links novel treatment evaluation with concurrent assess-
ment of biomarkers within a confirmatory phase 2–3 trial 
setting. Such a design will ultimately answer at least 
three research questions for several treatments and 
biomarkers. First, after a period of first-line chemo-
therapy, do targeted novel treatments provide signals of 
activity in different biomarker-defined populations, and 
second, do these targeted treatments improve outcomes 
definitively? Finally, is evidence of activity restricted to 
Research in context
Evidence before this study
The HER family has been a focus of attention in colorectal 
cancer since the development and licensing of the EGFR 
monoclonal antibodies panitumumab and cetuximab. The 
mechanism of action of these agents remains to be elucidated 
fully but has led to preclinical research implicating other HER 
family members in de-novo or evolving resistance. Several 
molecules (both monoclonal antibodies and tyrosine kinase 
inhibitors) have been developed that aim to overcome 
resistance pathways in selected patients. The most successful 
of these approaches to date has been a combination of 
trastuzumab and lapatinib, which has shown efficacy in a small 
cohort of patients with metastatic colorectal cancer 
harbouring HER2-positive tumours. All other drugs that have 
been developed specifically to interact with the HER family 
have so far failed to show additional efficacy in colorectal 
cancer, above that evident for cetuximab or panitumumab. 
AZD8931 was designed to inhibit EGFR, HER2, and HER3 
signalling. In two previous trials of AZD8931 as part of a 
combination strategy for breast cancer, no efficacy was 
recorded.
Added value of this study
Our study is the first randomised controlled trial to 
investigate use of AZD8931 in patients with colorectal cancer 
and in a prespecified molecular cohort of patients deemed 
most likely to be responsive to this approach. The multiarm 
multistage (MAMS) study design allowed optimisation of 
recruitment and early assessment of the drug in an efficient 
and effective manner.
Implications of the available evidence
AZD8931 showed no benefit in the first-line setting for 
metastatic colorectal cancer. The finding that this agent was 
ineffective in a molecularly defined subgroup of patients 
suggests that as monotherapy, AZD8931 has little to add in this 
disease type. The MAMS trial design has shown an ability to 
deliver an efficient and effective trial in molecularly defined 
cohorts of patients with metastatic colorectal cancer. 
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the biomarker-defined groups?11 Such a trial design fulfils 
the pressing need to deliver molecularly driven inter-
ventions to appropriately defined cohorts of patients in 
an efficient and effective fashion. The FOCUS4 pro-
gramme of trials investigates such a design in patients 
with advanced colorectal cancer.
FOCUS4 was set up to provide a trial platform for rapid 
identification of patients whose tumours can be charac-
terised either by the presence of specific mutations or by 
validated biomarkers that characterise biological cohorts. 
The trial uses an adaptive design that allows early 
preplanned interim analyses of molecular cohorts to 
review whether there is sufficient drug activity to justify 
continuing the trial being undertaken in that cohort.11 
Clinical trials are costly, and prudent direction of resources 
towards drugs that look the most promising could improve 
the efficiency with which new drugs can be evaluated. 
In this Article, we report the findings of one of these 
molecular cohorts (FOCUS4-D), which reached its first 
interim analysis trigger point in March, 2016. The aim of 
FOCUS4-D was to test the efficacy of AZD8931 in patients 
with colorectal cancer whose tumours are wild-type for 
BRAF, PIK3CA, KRAS, and NRAS mutations.
AZD8931 is an orally active, equipotent tyrosine kinase 
inhibitor of EGFR, HER2, and HER3 signalling. In-vitro 
analysis of AZD8931 in ligand-driven cell assays shows 
potency exceeding that of gefitinib and lapatinib in 
this system for EGFR, HER2, and HER3 inhibition.12 
In pharmaco kinetic and dynamic analyses, a direct 
relation was recorded between the total amount of 
AZD8931 in plasma and inhibition of EGFR phos-
phorylation.12 Within FOCUS4-D, we excluded patients 
with PTEN loss or somatic BRAF, PIK3CA, KRAS, and 
NRAS mutations. The rationale for the exclusion of 
patients with BRAF mutations relates to two specific sets 
of data. First, BRAF-mutant colorectal cancer has 
significantly worse prognosis than does disease with 
wild-type KRAS and NRAS.13 Second, despite some 
conflicting evidence, BRAF-mutant tumours gain no 
additional benefit from targeted EGFR inhibition.14 
Patients harbouring tumours with a PIK3CA mutation or 
PTEN loss were excluded specifically because data 
suggest the PI3K/AKT pathway is a resistance mechanism 
to EGFR inhibition.15
In the phase 2 Medical Research Council (MRC) COIN-B 
trial,16 patients who had metastatic KRAS wild-type 
tumours were treated with an intermittent strategy of 
oxaliplatin, intravenous fluorouracil, and folinic acid and 
randomised to either intermittent cetuximab (with 
intermittent chemotherapy) or continuous cetuximab 
Eligible patients
•  Advanced or metastatic colorectal cancer
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•  Consent to biomarker analysis
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Stable or responding disease after standard
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Figure 1: FOCUS4 trial programme schema
Registration and randomisation processes and molecular stratification of patients in FOCUS4. Molecular cohorts are arranged in a hierarchy from left to right, 
such that a patient with both a PIK3CA and KRAS mutation will be classified in the PIK3CA mutation cohort. Red coloured letters indicate the FOCUS4 subtrials, 
with FOCUS4-D shaded grey. FFPE=formalin-fixed paraffin-embedded.
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(including single-agent maintenance through the interval 
between chemotherapy). These trial data showed that use 
of maintenance cetuximab in the interval was associated 
with an improvement in the duration of the progression-
free interval from 3 months to 6 months.16 FOCUS4-D 
builds on these data to test if—in a more specific molecular 
cohort—AZD8931 will improve progression-free survival 
in the interval off chemotherapy.
Methods
Patients’ registration and biomarker assessment
We undertook the FOCUS4-D trial at 18 hospital sites in the 
UK. Patients aged 18 years and older with newly diagnosed 
locally advanced or metastatic colorectal cancer were 
eligible for registration in the FOCUS4 trial programme 
either at the start of a 16-week regimen of first-line 
chemotherapy or up to 12 weeks into the regimen. Patients 
could not be registered in FOCUS4 unless a CT scan had 
been done within 4 weeks of starting chemotherapy 
(preregistration CT scan). CT scans were obtained at 
8 weeks and 16 weeks after chemotherapy was started. 
A CT scan done at the end of the 16-week regimen was 
compared with the preregistration CT scan by local 
radiologists, using Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.1. Patients whose tumours 
had pro gressed were ineligible for randomisation and any 
further involvement with FOCUS4 ended at this time.
The 16-week duration of first-line chemotherapy was 
determined by reviewing data from three key trials: 
COIN,17 CAIRO3,18 and AIO0207.19 This period accounts 
for factors including maximum tumour response and 
tolerability by patients.
During the 16-week period of first-line chemotherapy, 
a sample of the patient’s tumour was sent to one of 
two dedicated FOCUS4 biomarker laboratories in Leeds 
and Cardiff (UK) for assessment and stratification of the 
patient into one of four molecular groups. Figure 1 
presents the molecular stratification hierarchy for the 
FOCUS4 trial programme. The technical components of 
the biomarkers and interlaboratory quality assurance 
have been described previously.20
Patients whose tumours had remained stable or 
responded to treatment according to CT were assessed 
for eligibility for FOCUS4-D. The biomarker assessment 
had to show wild-type status for BRAF, PIK3CA, KRAS, 
and NRAS, as well as PTEN expression on immuno histo-
chemistry. Figure 2 presents the FOCUS4-D trial design 
with eligibility criteria. Full inclusion and exclusion 
criteria are available in the trial protocol, published on 
the FOCUS4 website. In addition to the eligibility criteria, 
patients had to have had a minimum 3-week gap between 
the last dose of chemotherapy or biological therapy and 
before the first dose of trial drug; a WHO performance 
status of 0–2; and adequate organ function, ascertained 
by an estimated creatinine clearance greater than 
50 mL/min (according to local estimation method), 
serum bilirubin less than 1·5 × upper limit of normal 
(ULN), alanine amino transferase, aspartate amino trans-
ferase, and alkaline phosphatase less than 2·5 × ULN in 
the absence of liver metastases and less than 3·0 × ULN 
in presence of liver metastases, and a left-ventricular 
ejection fraction greater than 50% by multigated 
acquisition (MUGA) scan or echocardiography.
Ethics approval was granted by the National Research 
Ethics Service South Central Oxford—Panel C ethics 
committee (number 13/SC/0111). Regulatory approval was 
granted by the UK Medicines and Healthcare products 
Regulatory Agency (clinical trial authorisation [CTA] 
number 00316/0245/001-0001). All trial procedures and 
processes complied with the International Conference 
on Harmonisation’s Good Clinical Practice guidelines. 
We asked patients to sign a consent form for registration 
and for analysis of the biomarker panel; additional written 
informed consent was obtained before randomisation in 
FOCUS4-D.
Randomisation and masking
Randomisation was done by telephone to a centrally 
managed service at the MRC Clinical Trials Unit (CTU) 
at University College London (UCL). Patients were 
allocated to either AZD8931 or placebo by minimisation 
Placebo AZD8931
Registration and 16 weeks of first-line treatment
Consent for randomisation
Stop treatment due to progression, cumulative toxic effects, or patient’s choice
Clinic and trial assessments every 4 weeks for safety and toxicity and every
8 weeks for CT scans and RECIST assessment
Treatment after stopping trial therapy
•  Restart first-line treatment at clinical discretion
•  Patients could be eligible for treatment with oxaliplatin or irinotecan or
    entry into another clinical trial
Double-blinded randomisation, 3-week washout period between first-line
treatment and trial therapy
•  Responding or stable disease after first-line treatment
•  BRAF, PIK3CA, KRAS, and NRAS wild-type
•  PTEN detectable at any level on immunohistochemistry
•  Eligible for FOCUS4-D*
Figure 2: FOCUS4-D trial schema
RECIST=Response Evaluation Criteria in Solid Tumors. *Criteria were age older 
than 17 years, no brain metastases, adequate organ function, WHO performance 
status 0–2, not pregnant, and CT scan within 4 weeks before randomisation.
For the trial protocol see 
http://www.focus4trial.org
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with a random element of 20% (both patients and 
clinicians were masked to treatment allocation). 
Minimisation factors were: treating hospital site, site 
of primary tumour (right colon, left colon, or rectum), 
WHO performance status (0, 1, or 2), 16-week CT scan 
result (stable disease, partial response, or complete 
response), number of metastatic sites (none, one, or 
two or more), and first-line chemotherapy regimen 
(fluorouracil, capecitabine, or neither; both oxaliplatin 
and irinotecan, oxaliplatin only, irinotecan only, or 
neither; and cetuximab or panitu mumab, bevacizumab, 
or no monoclonal antibody). AZD8931 and placebo 
were identical in appearance, and were supplied by 
AstraZeneca (Cambridge, UK). Packaging, labelling, and 
distribution of AZD8931 and placebo were all undertaken 
by Fisher (Horsham, UK). Treatment was administered 
double-blind using an interactive web-based drug 
delivery system provided by Cenduit (Stirling, UK).
Procedures
We asked patients to take oral AZD8931 (40 mg twice daily) 
or placebo until disease progression, death, or toxic effects. 
We also requested that patients complete a diary card on 
which the number of pills taken every day was recorded.
 We assessed patients every 8 weeks by CT scan, which 
was reviewed at the treating hospital site according 
to RECIST, version 1.1. Measurements were collated 
centrally to ensure appropriate delineation of response 
and progression. Toxic effects and symptoms were 
assessed locally every 4 weeks from the start of trial 
treatment, using the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (version 3.0). 
We followed up patients until progressive disease was 
identified on a CT scan, at which point we recommended 
the patient should restart first-line chemotherapy.
Treatment was stopped in the event of grade 3 or worse 
toxic effects or persistent toxicities judged medically 
significant or not tolerated by the patient, until the toxicity 
resolved to grade 1 or better. After stopping treatment (for a 
maximum of 28 days), trial therapy could be re-initiated at 
a reduced dose. For the first event, treatment was restarted 
at 40 mg in the morning and 20 mg at night; for the second 
event, treatment was restarted at 20 mg twice a day. A third 
event resulted in treatment discontinuation. Any stoppage 
for 28 days or more was not permitted and the patient was 
discontinued from trial therapy.
Outcomes
The primary outcome of FOCUS4-D was progression-
free survival, defined as time from randomisation to 
either disease progression (according to RECIST 
criteria) or death from any cause. The trial could be 
extended to include overall survival as a secondary 
outcome if ade quate drug activity was seen for 
progression-free survival in the early interim analyses. 
Additional secondary end points included safety, toxicity, 
and tumour response.
Statistical analysis
FOCUS4 uses a multiarm multistage (MAMS) design 
that allows preplanned analyses to be done to inform a 
decision on whether to continue the trial.21 We used 
the nstage MAMS function in Stata, version 14.1, 
to calculate the operating characteristics for each 
molecular trial.22 For FOCUS4-D we anticipated a 
recruitment rate of nine patients per month if 100 sites 
were open. For the placebo group, we assumed a median 
progression-free survival of 4·6 months, based on a 
similar group of patients being followed up in the COIN 
trial.17 A target hazard ratio (HR) of 0·5 was sought for 
progression-free survival, with a randomisation ratio 
of 1:1. Table 1 summarises the operating characteristics 
for FOCUS4-D, with predicted timelines for the staged 
interim analyses. Power was maintained at 85% after 
correction for two interim analyses and one final 
analysis. Target recruitment was 174 patients, with 
the first interim analysis timed to occur when 
nine progression-free survival events had occurred in 
the control group. At every interim analysis, we 
compared the observed HR with the critical HR for 
that interim analysis (table 1). If the HR was above the 
critical value, trial closure could be considered on 
the grounds of an absence of sufficient drug activity.
When an interim analysis was triggered by the 
pre specified number of progression-free survival events 
in the control group, we cleaned and analysed data and 
presented the results at a closed and confidential 
meeting of the independent data monitoring committee 
(IDMC), who were not involved with conduct of the 
study. Recommendations to continue or close the study 
were made to the trial steering committee (TSC), who 
would recommend their decision. If a decision was 
made to close the study, the TSC allowed the trial 
management group (TMG) to see the data to ensure 
there were no objections to study closure. When all 
Stage 1* Stage 2† Stage 3‡
Outcome Progression-
free survival
Progression-
free survival
Progression-
free survival
One-sided α 0·5 0·2 0·025
Power (overall power 
maintained at 85%)
0·91 0·95 0·95
Target HR 0·5 ·· 0·5
Critical HR 1·00 0·81 0·70
Time required (months) 5·9 6·3 7·1
Cumulative time (months) 5·9 12·3 19·4
Cumulative events required in 
placebo group (total events 
required)
9 (15) 30 (50) 59 (101)
Total expected cumulative 
randomisations
54 110 174
HR=hazard ratio. *Safety and lack of sufficient activity. †Lack of sufficient activity. 
‡Efficacy.
Table 1: Operating characteristics for FOCUS4-D trial
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committees agreed to trial closure, we informed study 
sites, the pharma ceutical company (AstraZeneca), and 
the trial funders, and we permitted no further patients 
entry into the study.
We did all analyses according to a predefined 
statistical analysis plan that was agreed before any 
data inspection. The primary outcome was prespecified 
to be analysed by intention to treat (final analysis). 
We did interim analyses in the per-protocol sample, 
which we defined as patients who completed at least 
one cycle of trial treatment (≥28 days). Per-protocol 
analyses were done for sensitivity. We analysed data 
with Stata, version 14.1.
We censored patients according to the following 
criteria. For survival status, we censored patients on the 
date they were last known to be alive, either via collection 
of prescription from the drug delivery system or atten d-
ance at a follow-up visit or CT scan. For patients who 
died before any follow-up visit or CT scan, we used the 
date of death as the date of the event and assumed 
death without progression. For progression-free survival, 
we censored patients without progression on the date of 
the last CT scan showing no progression.
We used Kaplan-Meier curves to present survival data 
and Cox regression modelling to estimate HRs, which 
we adjusted for the stratification factors that were used to 
minimise patients into allocated groups. Because the 
numbers of patients and events were small, we adjusted 
using the method of inverse probability weighting,23 and 
using the bootstrap method to estimate CIs. We tested 
the proportional hazards assumption by regressing 
scaled Schoenfeld residuals against the log of time.24 
If evidence showed significant violation, we did a sensi-
tivity analysis using restricted mean sur vival analysis.21
The FOCUS4 trial programme is registered at 
controlled-trials.com, ISRCTN 90061546.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, or writing of the report. We informed the 
funder of results before submission of this Article and 
offered the funder the opportunity to comment on the 
data interpretation. DF and LB had access to raw data. 
RA had final responsibility for the decision to submit 
for publication.
Results
Between July 7, 2014, and March 7, 2016, 32 patients 
were randomised (16 into each treatment group) across 
18 hospitals in the UK (figure 3). The groups were well 
balanced in terms of baseline characteristics (table 2). 
The first interim analysis was triggered in March, 2016, 
when nine progression-free survival events had occurred 
in the placebo group. The IDMC reviewed the data as 
part of a closed confidential meeting and made a 
recommendation to close the trial based on insufficient 
drug activity, because the observed HR did not fall below 
the critical HR threshold of 1·0, which was predefined 
as part of the multistage sample size calculations 
(table 1). This decision was subsequently endorsed by 
both the TSC and TMG. Trial recruitment was closed, 
and during subsequent follow-up of patients already 
entered into the study, further progression-free survival 
events occurred, such that 31 of 32 patients had a 
progression-free survival event by the time of the 
132 wild-type, no loss of PTEN
391 successful
460 registered
16 placebo
1 did not receive
treatment
1 did not complete
first cycle
14 in per-protocol analysis
16 AZD8931
32 randomised to FOCUS4-D
End of registration disease assessment
80 complete or partial response or stable disease
and eligible for randomisation
34 not randomised*
14 randomised to FOCUS4-N
24 progressive disease
28 data not yet available 
1 did not receive
treatment
15 in per-protocol analysis
Assay preparation
54 not yet prepared
15 unsuccessful
Biomarker assay
249 mutated
4 BRAF test failure
6 other test failure, all successful 
tests wild-type
Figure 3: Trial profile
*Reasons for non-randomisation not recorded.
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final analysis on Aug 1, 2016. No patients were lost 
to follow-up. Median progression-free survival was 
3·48 months (95% CI 1·51–5·09) with placebo and 
2·96 months (1·94–5·62) with AZD8931 (adjusted HR 
1·10, 95% CI 0·47–3·57; p=0·95; figure 4).
Two patients did not receive any treatment (one in each 
group), and one further patient in the placebo group did 
not complete their first cycle. Therefore, 29 patients were 
included in the per-protocol sample (14 in the placebo 
group and 15 in the AZD8931 group). The Cox regression 
analysis within the per-protocol sample (for sensitivity)
generated an adjusted HR of 1·15 (95% CI 0·49–4·75; 
p=0·92) in favour of placebo. No statistical evidence was 
found that the proportional hazards assumption had 
been violated (Grambsch-Therneau test on log time 
scale, p=0·25 for intention-to-treat analysis and p=0·35 
for per-protocol analysis), but because of the small 
sample size, a sensitivity analysis using restricted mean 
survival time analysis at 4 months was done. However, 
this test did not alter the results for either the intention-
to-treat analysis (adjusted restricted mean 2·90 months 
[95% CI 2·34–3·46] in the placebo group vs 2·95 months 
[2·37–3·53] in the AZD8931 group; p=0·90 for difference) 
or the per-protocol analysis (3·08 months [2·61–3·56] vs 
3·05 months [2·48–3·63]; p=0·94 for difference).
Among the 32 randomised patients, 11 (34%) received 
first-line irinotecan and fluorouracil. After progression, 
only four (36%) of these patients returned to their first-line 
therapy. Reasons for not doing so were the clinician’s 
decision because of toxicity or disease progression. 
A further eight (25%) patients received first-line oxaliplatin 
plus capecitabine, and four (50%) of these patients 
returned to this regimen after progression. Reasons for 
not returning to first-line therapy were clinician’s 
decision (toxicity [n=1], progression [n=1], and reported 
asymptomatic [n=1]) and entering another trial (n=1). 
A further seven (22%) patients received irinotecan and 
fluorouracil plus cetuximab or panitumumab as first-line 
therapy, and only one (14%) patient returned to their 
first-line regimen after disease progression. The reasons 
for not returning to first-line therapy were patient’s choice 
(n=4), patient considered for resection (n=1), and missing 
data (n=1). Other first-line therapies included oxaliplatin 
and capecitabine plus bevacizumab (n=2), oxaliplatin 
and fluorouracil (n=2), capecitabine alone (n=1), and 
fluorouracil alone (n=1). 11 (34%) of 32 patients restarted 
their first-line therapy at the time of data collection. 
No patterns were noted in the reasons given for not 
restarting therapy. As of November, 2017, not all data for 
post-progression treatments were available.
Five of 32 patients needed dose reductions: one in 
the placebo group and four in the AZD8931 group. 
The patient in the placebo group had their evening dose 
reduced from 40 mg to 20 mg on their second cycle 
because of diarrhoea (grade 3). The dose reduc tions in the 
AZD8931 group were all evening dose reductions from 
40 mg to 20 mg on the second or third cycles and were 
because of skin rash (grade 2 [n=1] and grade 3 [n=3]). 
One patient in the AZD8931 group subsequently had a 
morning dose reduction from 40 mg to 20 mg on their 
fourth cycle, also because of skin rash (grade 3), and 
another subsequently had a morning dose reduction 
from 40 mg to 20 mg on their sixth cycle, for dry eyes 
(grade 3). All dose reductions were maintained within the 
currently available data. Only one patient explicitly gave 
the reason for stopping trial treatment as toxicity. This 
patient was assigned AZD8931 and reported grade 3 dry 
eyes, grade 2 skin ulceration, and grade 2 skin rash. 
No serious adverse events were reported for this patient. 
Overall, few toxic effects were reported. Adverse events of 
grade 1–2 are listed in the appendix. Skin rash was the 
Placebo (n=16) AZD8931 (n=16)
Age (years) 64 (58–74) 65 (57–71)
Sex
Male 13 (81%) 13 (81%)
Female 3 (19%) 3 (19%)
Current state of primary tumour
Resected primary 11 (69%) 8 (50%)
Unresected primary 5 (31%) 7 (44%)
Unresected local recurrence 0 1 (6%)
Timing of metastases
Metachronous 4 (25%) 4 (25%)
Synchronous 12 (75%) 11 (69%)
Missing data 0 1 (6%)
Site of primary of tumour
Right colon 5 (31%) 5 (31%)
Left colon 6 (38%) 6 (38%)
Rectum 5 (31%) 5 (31%)
WHO performance status
0 12 (75%) 11 (69%)
1 or 2 4 (25%) 5 (31%)
Disease assessment at end of first-line treatment
Partial response 8 (50%) 7 (44%)
Stable disease 8 (50%) 9 (56%)
Number of metastatic sites
One 6 (38%) 9 (56%)
Two or more 10 (63%) 7 (44%)
Fluoropyrimidine drug used during first-line treatment
Fluorouracil 11 (69%) 10 (63%)
Capecitabine 5 (33%) 6 (38%)
Oxaliplatin or irinotecan used during first-line treatment
Oxaliplatin only 6 (38%) 6 (38%)
Irinotecan only 9 (56%) 9 (56%)
Neither 1 (6%) 1 (6%)
Monoclonal antibody used during first-line treatment
Cetuximab or panitumumab 4 (25%) 3 (19%)
Bevacizumab 1 (6%) 1 (6%)
No antibody 11 (69%) 12 (75%)
Data are number of patients (%) or median (IQR).
Table 2: Baseline characteristics
See Online for appendix
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most frequent grade 3 adverse event, recorded in three 
(20%) of 15 patients in the AZD8931 group versus no 
patients in the placebo group; diarrhoea was the most 
frequent grade 3 adverse event in the placebo group, 
recorded in one patient (6%) versus one patient (7%) in 
the AZD8931 group (table 3). No grade 4 adverse events 
were reported. Five serious adverse events needed 
admission to hospital, four in the AZD8931 group 
(epigastric pain [grade 3]; back pain [grade 3], hyper-
bilirubinaemia [grade 4], and device-related infection 
[grade 2]; duodenal ulcer [grade 3]; and dehydration 
[grade 3, but subsequently fatal]) and one in the placebo 
group (chest infection [grade 3]). No treatment-related 
deaths were reported. Patients’ compliance was 85% in 
the placebo group and 75% in the AZD8931 group.
Discussion
The FOCUS4 programme has delivered its first result in 
a molecularly selected cohort of patients with advanced 
colorectal cancer. In FOCUS4-D, AZD8931 failed to pass 
the first stage of assessment within the MAMS trial 
design—ie, the predefined critical hazard ratio of 1·0 at 
stage 1 (lack of sufficient activity; table 1) was not reached. 
However, this trial has set a new paradigm in molecularly 
stratified trials in colorectal cancer.
Two phase 2, randomised, combination trials of 
AZD8931 have been done previously, both in patients 
with breast cancer. The MINT study25 was stopped 
because of lack of efficacy (NCT01151215). In this trial, 
AZD8931 (40 mg or 20 mg twice daily) was compared 
with placebo in combination with anastrozole in 
postmenopausal women with hormone receptor-positive 
locally advanced or metastatic breast cancer who had 
never had endocrine treatment. The second randomised 
trial (THYME) did not meet its primary objective of 
prolonged progression-free survival when AZD8931 was 
added to weekly paclitaxel in patients with advanced 
breast cancer and low expression of HER2 (NCT00900627). 
The primary hypothesis in the THYME study was that 
low HER2 expression was a driver for heterodimerisation, 
which would be inhibited by AZD8931. In FOCUS4-D, 
we were unable to investigate subgroups effectively 
because of the small sample size. Specific areas of 
interest include the effect of anti-EGFR agents in the 
chemotherapy induction phase and pre-randomisation 
(six patients in total) and the role of primary tumour 
location as a marker of response to treatment. 
The findings of these three trials indicate a need for 
greater understanding of EGFR family heterodimers and 
their dynamic interaction with targeted agents. To date, 
heterodimers have been poorly assessed in vitro and in 
vivo because of a paucity of effective methods, which 
might have hampered more complete scrutiny of 
therapeutic agents such as AZD8931.
FOCUS4-D is the first of the FOCUS4 molecular 
cohorts to reach its first MAMS-defined interim 
Number at risk
(number censored)
Placebo
AZD8931
0 2 4 6 8 10 12
16 (0)
16 (0)
10 (0)
12 (0)
6 (0)
6 (0)
2 (0)
3 (1)
2 (0)
2 (0)
2 (0)
0 (0)
0 (0)
0 (0)
Time since randomisation (months)
0
25
50
75
100
Adjusted HR 1·10, 95% CI 0·47–3·57; p=0·95
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)
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AZD8931
Figure 4: Progression-free survival (intention-to-treat analysis)
HR=hazard ratio.
Placebo (n=16) AZD8931 (n=15)*
Nausea 0 0
Vomiting 0 0
Diarrhoea 1 (6%) 1 (7%)
Stomatitis 0 0
Dry skin 0 0
Skin rash 0 3 (20%)
Acne 0 0
PPE 0 0
Anaemia 0 1 (7%)
Neutropenia 0 0
Thrombocytopenia 0 0
Hyperbilirubinaemia 0 1 (7%)
Elevated ALT or AST 0 0
Hypomagnesaemia 0 0
Cardiac toxicity 0 0
Pneumonitis 0 0
Infection 0 1 (7%)
Dry eyes 0 1 (7%)
Photophobia 0 0
Blurred vision 0 0
Conjunctivitis 0 0
Corneal ulcer 0 0
Fatigue 0 0
Paronychia 0 0
Epistaxis 0 0
Cystitis 0 0
Data are number of patients (%). Adverse events were graded according to the 
National Cancer Institute’s Common Terminology Criteria for Adverse Events, 
version 3.0. No grade 4 or 5 events were reported. Adverse events of 
grade 1–2 are listed in the appendix. ALT=alanine aminotransferase. 
AST=aspartate aminotransferase. PPE=palmar-plantar erythrodysaesthesia. 
*Data missing for one patient.
Table 3: Adverse events of grade 3 or worse
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analysis. The observed HR at the interim analysis was 
above the critical threshold for continuation of the trial, 
and the decision to close the trial was clearcut and 
unanimous across all oversight committees. We see 
this outcome as a success of the trial design, in that a 
decision to continue might have wasted clinical trial 
resources on recruiting and following up a further 
142 patients, and closing the trial prevented other 
patients from being given an ineffective but potentially 
harmful treatment. FOCUS4-D was designed to detect 
a target HR of 0·5. Therefore, the probability of a final 
analysis of 174 patients showing an HR of 0·5 when the 
noted HR at this interim analysis was 1·10 is 
exceptionally small.
A limitation of the FOCUS4-D study was that some 
deviation took place from the assumptions that we made 
in our sample size calculations. The final sample size is 
small, with recruitment of only 32 of the maximum 
expected target of 174 patients. The median progression-
free survival in the placebo group was 3·5 months, which 
is lower than we had anticipated in our sample size 
(4·6 months), and the higher event rate brought forward 
the trigger point for analysis (nine events in the placebo 
group). Owing to delays in site-opening of this complex 
trial, recruitment was also slower than anticipated, so 
this trigger occurred after randomisation of fewer 
patients than we had expected (32 instead of 54). 
However, since all but one patient had had a progression-
free survival event by the time of the final analysis, we are 
reassured that further follow-up would not alter the 
conclusions of the study, and there is little reason to 
suspect that a further 22 patients (which would take our 
total sample size to the expected 54 patients at this 
analysis) would have responded any differently to the 
32 patients reported here. Additionally, the fewer patients 
in the stage 1 analysis of lack of sufficient activity might 
increase any effect on outcome between the two 
treatment groups posed by trial imbalances in prognostic 
factors and choice of first-line treatment. For instance, 
the trial size makes it impossible to assess with any 
meaningful interpretation the effects of previous 
first-line treatment by EGFR inhibition with cetuximab 
or panitumumab (four patients in the placebo group and 
three patients in the AZD8931 group).
FOCUS4-D has shown no evidence of efficacy of 
single-agent EGFR, HER2, and HER3 inhibition with 
AZD8931 in patients with advanced colorectal cancer 
whose tumours are wild-type for BRAF, PIK3CA, KRAS, 
and NRAS after first-line induction therapy. Toxic effects 
were low, apart from skin rash in about 20% of patients. 
Early planned interim analyses with prespecified efficacy 
thresholds for lack of sufficient drug activity might be 
helpful in closing trials that are very unlikely to show 
benefit, which could facilitate more efficient use of 
clinical trial resources. New agents are currently being 
investigated for testing in this cohort of patients with all 
wild-type tumours.
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